Iridium [IRMD] vs Conmed [CNMD] Detailed Stock Comparison
Iridium
NASDAQ
Loading...
Conmed
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Iridium wins in 9 metrics, Conmed wins in 11 metrics, with 0 ties. Conmed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Iridium | Conmed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 44.39 | 14.94 | Conmed |
| Price-to-Book Ratio | 9.64 | 1.63 | Conmed |
| Debt-to-Equity Ratio | 0.00 | 87.93 | Iridium |
| PEG Ratio | 2.89 | -0.52 | Conmed |
| EV/EBITDA | 34.87 | 11.29 | Conmed |
| Profit Margin (TTM) | 26.61% | 8.31% | Iridium |
| Operating Margin (TTM) | 33.26% | 10.62% | Iridium |
| EBITDA Margin (TTM) | 33.26% | 10.62% | Iridium |
| Return on Equity | 23.75% | 11.69% | Iridium |
| Return on Assets (TTM) | 15.15% | 4.03% | Iridium |
| Free Cash Flow (TTM) | $16.81M | $153.88M | Conmed |
| Dividend Yield | 1.15% | 1.15% | Conmed |
| 1-Year Return | 50.85% | -31.66% | Iridium |
| Price-to-Sales Ratio (TTM) | 11.71 | 1.23 | Conmed |
| Enterprise Value | $857.88M | $2.49B | Conmed |
| EV/Revenue Ratio | 11.05 | 1.87 | Conmed |
| Gross Profit Margin (TTM) | 78.17% | 55.01% | Iridium |
| Revenue per Share (TTM) | $6 | $43 | Conmed |
| Earnings per Share (Diluted) | $1.61 | $3.54 | Conmed |
| Beta (Stock Volatility) | 1.03 | 1.19 | Iridium |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Iridium vs Conmed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Iridium | 2.28% | -2.54% | 3.24% | 23.83% | 39.06% | 31.74% |
| Conmed | 1.86% | -4.87% | -3.69% | -1.27% | -15.16% | -23.65% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Iridium | 50.85% | 133.41% | 244.01% | 178.28% | 722.50% | 722.50% |
| Conmed | -31.66% | -37.37% | -33.17% | 5.30% | 140.51% | 83.38% |
News Based Sentiment: Iridium vs Conmed
Iridium
News based Sentiment: MIXED
September presented a mixed bag for Iridium, with an earnings miss and a significant competitive threat from SpaceX offset by new contracts, a dividend increase, and continued institutional investment. The emergence of SpaceX as a competitor is a major development that warrants close attention, making this a significant month for the company's investment story.
Conmed
News based Sentiment: POSITIVE
CONMED delivered a strong second quarter and raised its full-year guidance, indicating positive momentum. The strategic shift towards recurring revenue and a consistent dividend policy are positive developments, though mixed analyst sentiment introduces some uncertainty. Overall, the month's events suggest a stable, moderately growing investment.
Performance & Financial Health Analysis: Iridium vs Conmed
| Metric | IRMD | CNMD |
|---|---|---|
| Market Information | ||
| Market Cap | $908.97M | $1.63B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 35,245 | 331,070 |
| 90 Day Avg. Volume | 46,555 | 427,663 |
| Last Close | $72.38 | $51.42 |
| 52 Week Range | $46.86 - $74.43 | $46.00 - $78.00 |
| % from 52W High | -2.76% | -34.08% |
| All-Time High | $74.43 (Sep 11, 2025) | $159.11 (Nov 01, 2021) |
| % from All-Time High | -2.75% | -67.68% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.03% |
| Quarterly Earnings Growth | 0.18% | -0.29% |
| Financial Health | ||
| Profit Margin (TTM) | 0.27% | 0.08% |
| Operating Margin (TTM) | 0.33% | 0.11% |
| Return on Equity (TTM) | 0.24% | 0.12% |
| Debt to Equity (MRQ) | 0.00 | 87.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.41 | $32.41 |
| Cash per Share (MRQ) | $4.17 | $1.10 |
| Operating Cash Flow (TTM) | $27.14M | $165.21M |
| Levered Free Cash Flow (TTM) | $7.10M | $163.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.15% | 1.15% |
| Last 12-Month Dividend | $0.81 | $0.60 |
Valuation & Enterprise Metrics Analysis: Iridium vs Conmed
| Metric | IRMD | CNMD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 44.39 | 14.94 |
| Forward P/E | 40.83 | 10.93 |
| PEG Ratio | 2.89 | -0.52 |
| Price to Sales (TTM) | 11.71 | 1.23 |
| Price to Book (MRQ) | 9.64 | 1.63 |
| Market Capitalization | ||
| Market Capitalization | $908.97M | $1.63B |
| Enterprise Value | $857.88M | $2.49B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 11.05 | 1.87 |
| Enterprise to EBITDA | 34.87 | 11.29 |
| Risk & Other Metrics | ||
| Beta | 1.03 | 1.19 |
| Book Value per Share (MRQ) | $7.41 | $32.41 |
Financial Statements Comparison: Iridium vs Conmed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IRMD | CNMD |
|---|---|---|
| Revenue/Sales | $20.41M | $321.26M |
| Cost of Goods Sold | $4.45M | $143.50M |
| Gross Profit | $15.95M | $177.75M |
| Research & Development | $877,362 | $12.95M |
| Operating Income (EBIT) | $6.79M | $15.96M |
| EBITDA | $7.00M | $34.21M |
| Pre-Tax Income | $7.33M | $7.67M |
| Income Tax | $1.55M | $1.64M |
| Net Income (Profit) | $5.77M | $6.04M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IRMD | CNMD |
|---|---|---|
| Cash & Equivalents | $50.33M | $35.49M |
| Total Current Assets | $75.14M | $639.00M |
| Total Current Liabilities | $8.47M | $283.15M |
| Long-Term Debt | $0 | $891.44M |
| Total Shareholders Equity | $90.05M | $977.64M |
| Retained Earnings | $59.32M | $560.13M |
| Property, Plant & Equipment | $59,221 | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IRMD | CNMD |
|---|---|---|
| Operating Cash Flow | $4.67M | $49.72M |
| Capital Expenditures | $-3.70M | $-3.78M |
| Free Cash Flow | $374,792 | $37.76M |
| Debt Repayment | N/A | $-180.59M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IRMD | CNMD |
|---|---|---|
| Shares Short | 151,794 | 2.09M |
| Short Ratio | 2.60 | 4.16 |
| Short % of Float | 0.02% | 0.09% |
| Average Daily Volume (10 Day) | 35,245 | 331,070 |
| Average Daily Volume (90 Day) | 46,555 | 427,663 |
| Shares Outstanding | 12.71M | 30.90M |
| Float Shares | 7.17M | 30.68M |
| % Held by Insiders | 0.37% | 0.01% |
| % Held by Institutions | 0.59% | 1.15% |
Dividend Analysis & Yield Comparison: Iridium vs Conmed
| Metric | IRMD | CNMD |
|---|---|---|
| Last 12-Month Dividend | $0.81 | $0.60 |
| Last 12-Month Dividend Yield | 1.15% | 1.15% |
| 3-Year Avg Annual Dividend | $0.88 | $0.73 |
| 3-Year Avg Dividend Yield | 0.75% | 0.24% |
| 3-Year Total Dividends | $2.64 | $2.20 |
| Ex-Dividend Date | Aug 18, 2025 | Mar 14, 2025 |